Resources
Pediatric Glioblastoma with Comprehensive Genomic Profiling
Patient: 7-year-old male with glioblastoma multiforme (WHO Grade IV) post–partial resection and chemoradiotherapy Clinical Testing:Alterations: TP53, CDKN2A, LATS1, ATM, BRCA2, RAD50, MSH2, MLH1, PMS2, XPC, EGFR, NF1, PIK3CA, PTEN, NPRL2,
Multi-Omics Insights Driving Personalized Therapy in Metastatic Triple-Negative Breast Cancer (TNBC)
Patient: 55 years – Female with metastatic triple-negative breast carcinoma (ER–, PR–, HER2 1+) Clinical Testing:Alterations: TP53 (p.D281E), MSH3 (p.R454*), PIK3CA (p.E542K), SMAD4 (p.E307*), SMARCA4 (p.D1127H), NF2 (p.E335*), CD274 (PD-L1, RNA)Genes: TP53, MSH3,
Staying Ahead of Resistance: Multi-Treated Breast Cancer
Patient: 52 years – Female with recurrent metastatic breast carcinoma (ER+, HER2–) Clinical Testing:Alterations: ESR1 (mutation), PIK3CA (VUS)Genes: ESR1, PIK3CATreatment Options: Sequential use of SERD/AI ± CDK4/6 inhibitors ± PI3K/AKT/mTOR inhibitors, guided by longitudinal
2025 ASCO Annual Meeting
1Cell.Ai at ASCO 2025: Explore Our Latest Research We’re excited to share 19 new posters and abstracts at the 2025 ASCO Annual Meeting. Our latest findings highlight the power of
AACR 2025 – Advancing Single-Cell Precision
We’re excited to share our latest research on true live single circulating tumor cell (CTC) capture with zero leukocyte contamination, enabling accurate multi-omic profiling across large cancer patient populations. This
1Cell.Ai: A Legacy of Innovation in Liquid Biopsy & Precision Oncology
We’ve contributed over 40+ publications—from ASCO to ESMO—highlighting advances in circulating tumor cells (CTCs), ctDNA, and AI-powered cancer diagnostics. Explore our collection of peer-reviewed studies, posters, and abstracts across: From
1Cell.Ai Featured in the Journal of Liquid Biopsy
Advancing the Science of ctDNA and CTC-Based Diagnostics Across Cancer Types We’re proud to be featured in five recent publications in the Journal of Liquid Biopsy, the official journal of
Single-Cell Genomics Reveals Resistance Signatures in Colorectal Cancer
Presented at ESMO Congress 2024 – Barcelona, Spain This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify enriched therapy-resistance signatures in advanced colorectal cancer patients. The findings
1Cell.Ai, Formerly OneCell Diagnostics, Launches OncoIncytes Integrating Multi-Modal Data for Precision Oncology
AI-powered precision oncology leader to enhance early-stage clinical studies with the introduction of next-generation technology Foster City, CA. & Mumbai, India (April 22, 2025) – OneCell Diagnostics today announced its
Oncology Think Tank Conclave – Delhi
Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell.Ai joined top clinicians, researchers, and industry leaders for a high-impact exchange on